Key points – In older patients with untreated CLL or small lymphocytic leukemia, treatment with idelalisib plus rituximab was generally well tolerated. The combination produced a very high response rate (97%), including 19% complete remission.
Key points – In older patients with untreated CLL or small lymphocytic leukemia, treatment with idelalisib plus rituximab was generally well tolerated. The combination produced a very high response rate (97%), including 19% complete remission.